https://doctransparency.com/doctor/fl/orlando/waleed-bolad-1194907667
Medicare Enrolled

Dr. Waleed Bolad, MD

Rheumatology · Orlando, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Mixed engagement
5750 MAJOR BLVD STE 150, Orlando, FL 32819
4074098118
In practice since 2007 (18 years)
NPI: 1194907667 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Bolad from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bolad? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Bolad

Dr. Waleed Bolad is a rheumatology in Orlando, FL, with 18 years in practice. Based on federal Medicare data, Dr. Bolad performed 80,770 Medicare services across 738 unique beneficiaries.

Between the years covered by Open Payments, Dr. Bolad received a total of $41,748 from 49 pharmaceutical and/or device companies across 1230 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Bolad is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice▲ Top 30% volume in FL$ $41,748 industry payments

Medicare Practice Summary

Medicare Utilization ↗
80,770
Medicare services
Top 30% in FL for rheumatology
738
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~4,487 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Certolizumab injection (Cimzia)52,000$4$11
Golimumab infusion (Simponi Aria)15,898$10$26
Abatacept infusion (Orencia)8,475$34$83
Denosumab injection (Prolia/Xgeva)2,520$18$44
Office visit, established patient (30-39 min)571$95$270
Administration of chemotherapy into vein, 1 hour or less371$93$345
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle305$51$189
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose116$100$191
Administration of chemotherapy into vein, each additional hour101$21$110
Joint injection, major joint80$60$259
Injection of additional new drug or substance into vein64$11$85
New patient office visit (45-59 min)57$121$415
Aspiration and/or injection of fluid large joint using ultrasound guidance56$76$237
Injection, methylprednisolone acetate, 80 mg42$9$40
Injection, diphenhydramine hcl, up to 50 mg32$1$2
Injection, methylprednisolone sodium succinate, up to 125 mg29$4$60
Injection, methylprednisolone acetate, 40 mg22$6$30
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less17$40$270
Office visit, established patient (20-29 min)14$67$184
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
30.2% high complexity
69.0% medium
0.8% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$41,748
Total received (2018-2024)
Avg $5,964/year across 7 years
Top 14% in FL for rheumatology
49
Companies
1,230
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$20,577 (49.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$16,310 (39.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$4,390 (10.5%)
Scientific / Research
Research funding and grants
$471 (1.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$5,795
2023
$9,376
2022
$12,234
2021
$2,553
2020
$5,318
2019
$3,538
2018
$2,933

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Mallinckrodt Hospital Products Inc.
$15,222
UCB, Inc.
$3,318
GENZYME CORPORATION
$2,869
Janssen Biotech, Inc.
$2,364
Amgen Inc.
$2,306
Horizon Therapeutics plc
$1,708
PFIZER INC.
$1,560
ABBVIE INC.
$1,390
Novartis Pharmaceuticals Corporation
$1,294
GlaxoSmithKline, LLC.
$1,175
AbbVie Inc.
$1,035
AbbVie, Inc.
$949
Lilly USA, LLC
$910
AstraZeneca Pharmaceuticals LP
$778
Aurinia Pharma U.S., Inc.
$738
Genentech USA, Inc.
$460
E.R. Squibb & Sons, L.L.C.
$340
Sobi, Inc
$319
ANI Pharmaceuticals, Inc.
$318
Celgene Corporation
$313
Mallinckrodt Enterprises LLC
$302
Janssen Pharmaceuticals, Inc
$294
Mallinckrodt LLC
$194
Boehringer Ingelheim Pharmaceuticals, Inc.
$177
SOBI, INC
$176
SANOFI-AVENTIS U.S. LLC
$145
Antares Pharma, Inc.
$123
Alexion Pharmaceuticals, Inc.
$114
Ferring Pharmaceuticals Inc.
$108
NeuroMetrix Inc
$99
Radius Health, Inc.
$81
Horizon Pharma plc
$65
DePuy Synthes Sales Inc.
$59
Sandoz Inc.
$54
Ultragenyx Pharmaceutical Inc.
$48
Fresenius Kabi USA, LLC
$47
Cardinal Health Inc
$43
Organon Llc
$40
Kyowa Kirin, Inc.
$27
Kiniksa Pharmaceuticals International, plc
$25
Teva Pharmaceuticals USA, Inc.
$22
Fidia Pharma USA Inc.
$20
Sebela Pharmaceuticals Inc.
$19
Hikma Pharmaceuticals USA
$19
Kiniksa Pharmaceuticals, Ltd.
$19
Boston Scientific Corporation
$19
Flexion Therapeutics, Inc.
$18
Mission Pharmacal Company
$13
MEDAC PHARMA, INC.
$13
Top 3 companies account for 51.3% of total payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · Actemra · Aquoral · Arcalyst · BENLYSTA · Bimzelx · COSENTYX · CRYSVITA · CYLTEZO · Cimzia · Crysvita · EUFLEXXA · EVENITY · Enbrel · FORTEO · GENERAL PAIN MANAGEMENT · HADLIMA · HUMIRA · HYM/HYN · HYRIMOZ · Humira · IDACIO · INFLECTRA · KEVZARA · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · MONOVISC · Mitigare · NUCALA · OFEV · ORENCIA · ORTHOVISC · OTREXUP · Otezla · Otrexup · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RENFLEXIS · RIDAURA · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · TALTZ · TAVNEOS · TREMFYA · Truxima · Tymlos · XELJANZ · XYOSTED · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (49%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $52 per 100 Medicare services performed
Looking for a rheumatology in Orlando?
Compare rheumatologys in the Orlando area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
40
Per 100K population
2.8
County median income
$77,011
Nearest hospital
CENTRAL FLORIDA BEHAVIORAL HOSPITAL
5.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Bolad is a mixed practice specialist, with above-average Medicare volume (top 30% in FL), and high industry engagement (mixed engagement, top 14%), with 18 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Bolad experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Bolad performed 52,000 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bolad receive payments from pharmaceutical companies?
Yes. Dr. Bolad received a total of $41,748 from 49 companies across 1,230 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bolad's costs compare to other rheumatologys in Orlando?
Dr. Bolad's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bolad) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →